Johnson & Johnson Stock News

Retirees and older individuals are among the biggest demographics who tune into Jim Cramer's Mad Money show.

The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.

Over the past ten years, Johnson & Johnson (NYSE: JNJ) has delivered an impressive $157 Bil back to its investors through cash distributions via dividends and buybacks. This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable 26% year-to-date return, significantly outpacing the broader healthcare sector and demonstra...

Investors who find themselves awake at night thinking about their portfolios, fear not.

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg  Approval was based on PROTOSTAR study, which showed pediatric patients receiving TREMFYA ® achieved high levels of skin clearance vs. placebo at Week 16 H...

Some stocks simply pay a regular dividend. The smarter ones also raise their dividend payout every year, putting more cash in their shareholders' pockets.

Dividend Aristocrats, tracked by NOBL, outperformed SPY in August but lagged year-to-date, with notable dispersion among individual stock returns. Dividend growth remains robust, with 55 of 69 Aristocrats already raising payouts in 2025 at an average rate of 5.19%, nearing last year's pace. 22 Dividend Aristocrats appear both undervalued and offer a projected long-term annualized return of at l...

Johnson & Johnson (JNJ 0.57%) is a longtime healthcare leader with numerous positive qualities. These include its 62 consecutive years of dividend increases, which surpass the 50 required to be recognized as a Dividend King.